KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Total Debt

Last Annual Value

1.45M

3-Year CAGR

-24%

5-Year CAGR

-30%

10-Year CAGR

-16%

KT

Kalaris Therapeutics Inc Competitors Analysis of Total Debt

KLRS · NASDAQ
CompanyTotal Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
1.45M
N/A-45.5%N/A 
13.42M
-5.7%N/AN/A
10.94M
-13.5%44.4%N/A
1.58M
-27.8%N/AN/A
112.06K
N/AN/AN/A
40.66M
-5.5%-3.6%N/A
91.70M
7.4%-2.3%N/A
5.22M
-32.8%47.7%N/A
61.65M
-45.2%-27.3%N/A
736.00K
-45.7%-35.4%N/A
825.00K
-74.8%9.1%N/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7